Asgard Therapeutics Secures €30M Series A Financing Led by JJDC and RV Invest to Advance First-in-Class In Vivo Reprogramming Therapy AT-108

Mar 15, 2024 04:27 CST Updated 04:27

Asgard Therapeutics

Cancer Immunotherapy Researcher

RV Invest

Venture Capital Firms

Johnson & Johnson Development Corporation

Healthcare-Focused Venture Capital Firm

Novo Holdings

Venture Capital and Asset Management Firms

Boehringer Ingelheim Venture Fund

Biomedical Venture Capital Fund

Industrifonden

Venture Capital Firm

▎WuXiEdited by Kant Content Team

Asgard Therapeutics Announces €30 Million Series A FinancingThese funds will be used to support its lead program, AT-108, to reach the status of supporting an IND submission by 2026, expand and strengthen its R&D team, and drive new cell reprogramming approaches and delivery platforms to enhance the product pipeline.This round of financing was co-led by RV Invest and Johnson & Johnson Innovation (JJDC), with existing investors Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden also participating in the investment.

AT-108 is a potential “first-in-class,” off-the-shelf gene therapy.AT-108 can reprogram cancer cells in patients into conventional type 1 dendritic cells (cDC1s)., a rare subset of immune cells that is crucial for an effective anti-tumor immune response. These induced cDC1s present individual-specific cancer antigens to the immune system, triggering personalized and systemic anti-cancer immune responses.AT-108 is a replication-deficient adenovirus vector therapy that delivers three transcription factors to tumor cells, rewriting their gene expression profile and reprogramming them into immunogenic cDC1 cells.

Based on multiple articles published inScience ImmunologyThe paper onAT-108 achieved preclinical proof-of-concept in patient-derived in vitro models as well as in rodent in vivo models. Even as a monotherapy, it elicited a potent antitumor immune response and abscopal effect.

Dr. Cristiana Pires is one of the co-founders of Asgard Therapeutics and has served as the company's CEO since its inception. During her postdoctoral research in Dr. Filipe Pereira’s lab, she focused on dendritic cell reprogramming strategies to modulate immune responses, which ultimately led to the establishment of Asgard Therapeutics. As CEO, she has already secured over 1.5 million euros in funding for the company. By combining her pharmacological and scientific background with entrepreneurial experience, Dr. Pires is working to bring AT-108 to patients.

Everyone is watching

As a CTDMO under WuXi AppTec that focuses on cell and gene therapies, WuXi Advanced Therapies is committed to accelerating and transforming the development, testing, manufacturing, and commercialization of gene and cell therapies as well as other advanced therapies. WuXi Advanced Therapies can help global customers bring more innovative treatments to market sooner, benefiting patients. If you have related business needs, please click on the image below to fill in the specific information.

▲If you have any business needs, please long press to scan the QR code above, or click "Read more" at the end of the article to access the business对接 platform and fill in your business needs information.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology. Retrieved March 14, 2024, from https://www.asgardthx.com/asgard-therapeutics-announces-e30-million-series-a-financing-to-advance-its-first-in-class-in-vivo-cell-reprogramming-platform-for-immuno-oncology/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.

Share，PointLike，In view，Focusing on Global Biomedical Health Innovation